Hypera S.A.: peers
Hypera S.A. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Regencell Bioscience Holdings Limited, Dermapharm Holding SE, Supernus Pharmaceuticals, Inc., Trulieve Cannabis Corp., Almirall, S.A.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Hypera S.A.base HYPE3.SA · 🇧🇷 BR Percentile in Healthcare Percentile in Brazil | Regencell Bioscience Holdings Limited RGC · 🇭🇰 HK Percentile in Healthcare Percentile in Hong Kong | Dermapharm Holding SE DMP.F · 🇩🇪 DE Percentile in Healthcare Percentile in Germany | Supernus Pharmaceuticals, Inc. SUPN · 🇺🇸 US Percentile in Healthcare Percentile in USA | Perrigo Company plc PRGO · 🇮🇪 IE Percentile in Healthcare Percentile in Ireland | Trulieve Cannabis Corp. TCNNF · 🇺🇸 US Percentile in Healthcare Percentile in USA | Bausch Health Companies Inc. BHC.TO · 🇨🇦 CA Percentile in Healthcare Percentile in Canada | Almirall, S.A. ALM.MC · 🇪🇸 ES Percentile in Healthcare Percentile in Spain | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $2.5 BNov 18, 2026 · Market dataEstimate4th of 8 | $2.7 BAug 1, 2026 · Market data3rd of 8 | $2.3 BAug 1, 2026 · Market data5th of 8 | $2.8 BAug 1, 2026 · Market data2nd of 8 | $2.2 BOct 30, 2026 · Market data6th of 8 | $2.1 BAug 1, 2026 · Market data7th of 8 | $3.1 BOct 31, 2026 · Market data1st of 8 | $2.0 Blast known, Jan 5, 2024 · Market dataLast known value: no current one8th of 8 | $2.4 B8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | —— | —— | $719 MFY2025 · SEC5th of 5 | $4.3 BFY2025 · SEC2nd of 5 | $1.2 BFY2025 · SEC4th of 5 | $10.3 BFY2025 · SEC1st of 5 | $1.2 BFY2025 · ESEF3rd of 5 | $1.2 B5 ranked |
| Net income (Higher is better) | —— | $-12 MFY2026 · SEC4th of 7 | $148 MFY2025 · Wikidata2nd of 7 | $-39 MFY2025 · SEC5th of 7 | $-1.4 BFY2025 · SEC7th of 7 | $-116 MFY2025 · SEC6th of 7 | $157 MFY2025 · SEC1st of 7 | $52 MFY2025 · ESEF3rd of 7 | $-12 M7 ranked |
| Employees (Better neither way: ranked highest first) | 9,000As on 2022 · Profile2nd of 7 | —— | 3,4972023 · Profile5th of 7 | 575As on 2021 · Profile7th of 7 | 8,900As on 2022 · Profile3rd of 7 | 4,700As on 2020 · Profile4th of 7 | 21,600As on 2020 · Profile1st of 7 | 1,7732019 · Profile6th of 7 | 4,7007 ranked |
| Growth | |||||||||
| Market cap change, 30 days (Higher is better) | —— | —— | —— | —— | —— | —— | +40.6%30 days to Oct 31, 2026 · Market dataonly one with it | —— | +40.6%— |
| Revenue growth (Higher is better) | ———— | ———— | ———— | +8.6%FY2025 · SEC2nd of 547th57th | -2.8%FY2025 · SEC5th of 521st16th | -0.5%FY2025 · SEC4th of 525th28th | +6.7%FY2025 · SEC3rd of 542nd44th | +17.1%FY2025 · ESEF1st of 563rd76th | +6.7%5 ranked |
| Revenue growth, 3 years a year (Higher is better) | ———— | ———— | ———— | +2.5%FY2025 · SEC2nd of 435th42nd | -1.5%FY2025 · SEC4th of 423rd12th | -1.0%FY2025 · SEC3rd of 424th29th | +8.1%FY2025 · SEC1st of 449th54th | ———— | +0.8%4 ranked |
| Earnings per share growth (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | +358.4%FY2025 · ESEFonly one with it96th99th | +358.4%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | ———— | ———— | 89.6%FY2025 · SEC1st of 392nd97th | 35.1%FY2025 · SEC3rd of 321st55th | 60.2%FY2025 · SEC2nd of 353rd74th | ———— | ———— | 60.2%3 ranked |
| Operating margin (Higher is better) | ———— | ———— | ———— | -8.7%FY2025 · SEC4th of 549th28th | -26.4%FY2025 · SEC5th of 539th6th | 12.2%FY2025 · SEC2nd of 576th73rd | 17.7%FY2025 · SEC1st of 585th64th | 6.6%FY2025 · ESEF3rd of 567th36th | 6.6%5 ranked |
| Net margin (Higher is better) | ———— | ———— | ———— | -5.4%FY2025 · SEC3rd of 553rd33rd | -33.5%FY2025 · SEC5th of 536th12th | -9.8%FY2025 · SEC4th of 548th27th | 1.5%FY2025 · SEC2nd of 563rd44th | 4.2%FY2025 · ESEF1st of 568th45th | -5.4%5 ranked |
| Free cash flow margin (Higher is better) | ———— | ———— | ———— | 6.4%FY2025 · SEC4th of 565th59th | 3.4%FY2025 · SEC5th of 559th21st | 19.4%FY2025 · SEC1st of 587th87th | 9.8%FY2025 · SEC3rd of 571st64th | 12.6%FY2025 · ESEF2nd of 576th74th | 9.8%5 ranked |
| Return on equity (Higher is better) | ———— | -128.5%FY2026 · SEC5th of 518th12th | ———— | -3.7%FY2025 · SEC2nd of 570th38th | -39.3%FY2025 · SEC4th of 549th9th | -9.7%FY2025 · SEC3rd of 566th33rd | ———— | 3.2%FY2025 · ESEF1st of 575th24th | -9.7%5 ranked |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | 7.0×price Nov 18, 2026 · Market dataonly one with it8th41st | ———— | 15.7׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | ———— | ———— | ———— | 7.0×— |
| Price to sales (Better neither way: ranked highest first) | 1.6×price Nov 18, 2026 · Market data1st of 327th72nd | ———— | 2.1׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 3.2׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 0.5×price Oct 30, 2026 · Market data2nd of 39th29th | 2.0׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 0.3×price Oct 31, 2026 · Market data3rd of 34th6th | ———— | 0.5×3 ranked |
| Price to book (Better neither way: ranked highest first) | 1.1×price Nov 18, 2026 · Market data1st of 221st41st | 201.9׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 4.0׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 2.6׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 0.8×price Oct 30, 2026 · Market data2nd of 214th4th | 1.9׆price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | ———— | 0.9×2 ranked |
| Free cash flow yield (Higher is better) | ———— | -0.1%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | ———— | 1.6%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 6.6%price Oct 30, 2026 · Market data2nd of 291st46th | 10.7%†price Aug 1, 2026 · Market datanot ranked: old priceold priceold price | 32.6%price Oct 31, 2026 · Market data1st of 299th99th | ———— | 19.6%2 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | ———— | ———— | ———— | 1.2×FY2025 · SEC2nd of 279th78th | 0.1×FY2025 · SEC1st of 223rd16th | ———— | ———— | 0.7×2 ranked |
| Net debt to EBITDA (Lower is better) | ———— | ———— | ———— | ———— | ———— | -0.5×FY2025 · SEC1st of 220th12th | 6.5×FY2025 · SEC2nd of 291st74th | ———— | 3.0×2 ranked |
| Interest cover (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | 1.1×FY2025 · SEConly one with it76th56th | ———— | 1.1×— |
| Piotroski F-score (Higher is better) | —— | —— | —— | —— | 4 of 9FY2025 · SEC2nd of 2 | 6 of 9FY2025 · SEC1st of 2 | —— | —— | 5.0 of 92 ranked |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 2 of 8FY2026 · Scorecard7th of 7 | 2 of 2FY2025 · Scorecard1st of 7 | 6 of 15FY2025 · Scorecard5th of 7 | 9 of 26FY2025 · Scorecard6th of 7 | 7 of 17FY2025 · Scorecard4th of 7 | 14 of 22FY2025 · Scorecard3rd of 7 | 4 of 5FY2025 · Scorecard2nd of 7 | 41% passed7 ranked |
| Valuation checks (Higher is better) | —— | —— | —— | —— | 3 of 6FY2025 · Scorecard1st of 2 | —— | 2 of 6FY2025 · Scorecard2nd of 2 | —— | 42% passed2 ranked |
| Growth checks (Higher is better) | —— | 0 of 2FY2026 · Scorecard5th of 7 | 1 of 1FY2025 · Scorecard1st of 7 | 2 of 6FY2025 · Scorecard4th of 7 | 0 of 6FY2025 · Scorecard5th of 7 | 0 of 6FY2025 · Scorecard5th of 7 | 6 of 6FY2025 · Scorecard1st of 7 | 2 of 2FY2025 · Scorecard1st of 7 | 33% passed7 ranked |
| Profitability checks (Higher is better) | —— | 0 of 3FY2026 · Scorecard5th of 7 | 1 of 1FY2025 · Scorecard1st of 7 | 0 of 5FY2025 · Scorecard5th of 7 | 0 of 5FY2025 · Scorecard5th of 7 | 2 of 5FY2025 · Scorecard4th of 7 | 3 of 4FY2025 · Scorecard2nd of 7 | 2 of 3FY2025 · Scorecard3rd of 7 | 40% passed7 ranked |
| Financial health checks (Higher is better) | —— | 1 of 2FY2026 · Scorecard3rd of 5 | —— | 3 of 3FY2025 · Scorecard1st of 5 | 2 of 4FY2025 · Scorecard3rd of 5 | 4 of 5FY2025 · Scorecard2nd of 5 | 2 of 5FY2025 · Scorecard5th of 5 | —— | 50% passed5 ranked |
| Shareholder returns checks (Higher is better) | —— | 1 of 1FY2026 · Scorecard1st of 5 | —— | 1 of 1FY2025 · Scorecard1st of 5 | 4 of 5FY2025 · Scorecard5th of 5 | 1 of 1FY2025 · Scorecard1st of 5 | 1 of 1FY2025 · Scorecard1st of 5 | —— | 100% passed5 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | —— | 0.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4 | —— | 97.9%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4 | 110.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4 | —— | 63.4%2026-Q2 · 13F3rd of 4 | —— | 80.7%4 ranked |
| Institutions holding (Better neither way: ranked highest first) | —— | 312026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 4 | —— | 2942026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 4 | 3362026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 4 | —— | 2202026-Q2 · 13F3rd of 4 | —— | 2574 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | —— | +0.1 pp2026-Q2 against 2026-Q1 · 13F4th of 4 | —— | +3.5 pp2026-Q2 against 2026-Q1 · 13F2nd of 4 | +6.6 pp2026-Q2 against 2026-Q1 · 13F1st of 4 | —— | +1.1 pp2026-Q2 against 2026-Q1 · 13F3rd of 4 | —— | +2.3 pp4 ranked |
| Dividends | |||||||||
| Dividend yield (Higher is better) | ———— | ———— | ———— | ———— | 7.2%FY2025 · SEConly one with it95th— | ———— | ———— | ———— | 7.2%— |
| Shareholder yield (Higher is better) | ———— | ———— | ———— | ———— | 7.2%FY2025 · SEConly one with it86th86th | ———— | ———— | ———— | 7.2%— |
| Dividend per share (Better neither way: ranked highest first) | —— | —— | —— | —— | $1.16FY2025 · SEConly one with it | —— | —— | —— | $1.16— |
| Years of dividend raises (Higher is better) | —— | —— | —— | —— | 9to 2025 · SEConly one with it | —— | —— | —— | 9— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Hypera S.A.: Estimate: B3 São Paulo close of 18 Nov 2026 x the share count implied by the market cap reported for 01 Aug 2026; Regencell Bioscience Holdings Limited: How market caps are worked out; Dermapharm Holding SE: How market caps are worked out; Supernus Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Perrigo Company plc: How market caps are worked out; Trulieve Cannabis Corp.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Bausch Health Companies Inc.: TMX Group, TSX and TSXV listed issuers (monthly); Almirall, S.A.: How market caps are worked out.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Hypera S.A. | — | — | — |
| Regencell Bioscience Holdings Limited | — | — | — |
| Dermapharm Holding SE | — | — | — |
| Supernus Pharmaceuticals, Inc. | -8.7%FY2025 | 49th percentile in Healthcaremedian -7.7%, 674 companies | 28th percentile in USAmedian 3.5%, 2,594 companies |
| Perrigo Company plc | -26.4%FY2025 | 39th percentile in Healthcaremedian -7.7%, 674 companies | 6th percentile in Irelandmedian 9.3%, 25 companies |
| Trulieve Cannabis Corp. | 12.2%FY2025 | 76th percentile in Healthcaremedian -7.7%, 674 companies | 73rd percentile in USAmedian 3.5%, 2,594 companies |
| Bausch Health Companies Inc. | 17.7%FY2025 | 85th percentile in Healthcaremedian -7.7%, 674 companies | 64th percentile in Canadamedian 8.7%, 114 companies |
| Almirall, S.A. | 6.6%FY2025 | 67th percentile in Healthcaremedian -7.7%, 674 companies | 36th percentile in Spainmedian 9.2%, 79 companies |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Hypera S.A. | Regencell Bioscience Holdings Limited | Dermapharm Holding SE | Supernus Pharmaceuticals, Inc. | Perrigo Company plc | Trulieve Cannabis Corp. | Bausch Health Companies Inc. | Almirall, S.A. |
|---|---|---|---|---|---|---|---|---|
| 2025 | — | — | — | $719 MSEC5th | $4.3 BSEC2nd | $1.2 BSEC4th | $10.3 BSEC1st | $1.2 BESEF3rd |
| 2024 | — | — | — | $662 MSEC5th | $4.4 BSEC2nd | $1.2 BSEC3rd | $9.6 BSEC1st | $1.1 BESEF4th |
| 2023 | — | — | $1.2 BWD3rd | $608 MSEC5th | $4.7 BSEC2nd | $1.1 BSEC4th | $8.8 BSEC1st | — |
| 2022 | — | — | $1.1 BWD4th | $667 MSEC5th | $4.5 BSEC2nd | $1.2 BSEC3rd | $8.1 BSEC1st | — |
| 2021 | — | — | $1.1 BWD3rd | $580 MSEC5th | $4.1 BSEC2nd | $932 MSEC4th | $8.4 BSEC1st | — |
| 2020 | — | — | $905 MWD3rd | $520 MSEC5th | $4.1 BSEC2nd | $522 MSEC4th | $8.0 BSEC1st | — |
| 2019 | — | — | $785 MWD4th | $393 MSEC5th | $3.9 BSEC2nd | $253 MSEC6th | $8.6 BSEC1st | $957 MWD3rd |
| 2018 | — | — | $675 MWD3rd | $409 MSEC4th | $4.7 BSEC2nd | — | $8.4 BSEC1st | — |
| 2017 | — | — | $527 MWD3rd | $302 MSEC4th | $4.9 BSEC2nd | — | $8.7 BSEC1st | — |
| 2016 | — | — | $492 MWD3rd | $215 MSEC4th | $5.3 BSEC2nd | — | $9.7 BSEC1st | — |
| 2015 | — | — | $427 MWD3rd | $147 MSEC4th | $4.2 BSEC2nd | — | $10.4 BSEC1st | — |
| 2014 | — | — | $519 MWD3rd | $93 MSEC4th | $3.9 BSEC2nd | — | $8.2 BSEC1st | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Hypera S.A.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Regencell Bioscience Holdings LimitedRGC · 🇭🇰 Hong KongSame industry: Pharmaceutical · Similar size: $2.7 B market cap against $2.5 B · Ratios of the last two fiscal years on fileMarket cap $2.7 B (Aug 1, 2026)85 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Dermapharm Holding SEDMP.F · 🇩🇪 GermanySame industry: Pharmaceutical · Similar size: $2.3 B market cap against $2.5 B · Ratios of the last two fiscal years on fileMarket cap $2.3 B (Aug 1, 2026) · revenue $1.1 B (year to December 2022)84 of 100 (industry or sector 50 + size 30 + figures on file 5)In the group
- Supernus Pharmaceuticals, Inc.SUPN · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $2.8 B market cap against $2.5 B · Ratios of the last two fiscal years on fileMarket cap $2.8 B (Aug 1, 2026) · revenue $719 M (year to December 2025)84 of 100 (industry or sector 50 + size 29 + figures on file 5)In the group
- Perrigo Company plcPRGO · 🇮🇪 IrelandSame industry: Pharmaceutical · Similar size: $2.2 B market cap against $2.5 B · Ratios of the last two fiscal years on fileMarket cap $2.2 B (Oct 30, 2026) · revenue $4.3 B (year to December 2025)84 of 100 (industry or sector 50 + size 29 + figures on file 5)In the group
- Trulieve Cannabis Corp.TCNNF · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $2.1 B market cap against $2.5 B · Ratios of the last two fiscal years on fileMarket cap $2.1 B (Aug 1, 2026) · revenue $1.2 B (year to December 2025)84 of 100 (industry or sector 50 + size 29 + figures on file 5)In the group
- Bausch Health Companies Inc.BHC.TO · 🇨🇦 CanadaSame industry: Pharmaceutical · Similar size: $3.1 B market cap against $2.5 B · Ratios of the last two fiscal years on fileMarket cap $3.1 B (Oct 31, 2026) · revenue $10.3 B (year to December 2025)84 of 100 (industry or sector 50 + size 29 + figures on file 5)In the group
- Almirall, S.A.ALM.MC · 🇪🇸 SpainSame industry: Pharmaceutical · Similar size: $2.0 B market cap against $2.5 B · Ratios of the last two fiscal years on fileMarket cap $2.0 B (last known, Jan 5, 2024) · revenue $1.2 B (year to December 2025)83 of 100 (industry or sector 50 + size 28 + figures on file 5)In the group
- Fagron NVFAGR.BR · 🇧🇪 BelgiumSame industry: Pharmaceutical · Similar size: $1.9 B market cap against $2.5 B · Ratios of the last two fiscal years on fileMarket cap $1.9 B (Aug 1, 2026) · revenue $944 M (year to December 2024)83 of 100 (industry or sector 50 + size 28 + figures on file 5)+ Add
- Dimed Distribuidora de MedicamentosPNVL3.SA · 🇧🇷 BrazilSame industry: Pharmaceutical · 6.5× smaller by market cap · Same country: BrazilMarket cap $388 M (last known, Jan 5, 2024)83 of 100 (industry or sector 50 + size 18 + country 15)+ Add
- Organon & Co.OGN · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $3.6 B market cap against $2.5 B · Ratios of the last two fiscal years on fileMarket cap $3.6 B (Oct 19, 2026) · revenue $6.2 B (year to December 2025)83 of 100 (industry or sector 50 + size 28 + figures on file 5)+ Add
- Faes Farma, S.A.FAE.MC · 🇪🇸 SpainSame industry: Pharmaceutical · Similar size: $1.7 B market cap against $2.5 B · Ratios of the last two fiscal years on fileMarket cap $1.7 B (Aug 1, 2026) · revenue $688 M (year to December 2025)82 of 100 (industry or sector 50 + size 27 + figures on file 5)+ Add
- ANI Pharmaceuticals, Inc.ANIP · 🇺🇸 USASame industry: Pharmaceutical · Similar size: $1.6 B market cap against $2.5 B · Ratios of the last two fiscal years on fileMarket cap $1.6 B (Oct 9, 2026) · revenue $883 M (year to December 2025)82 of 100 (industry or sector 50 + size 27 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.